MedImmune, NGM ally to develop drugs for obesity, diabetes

06/18/2013 | PharmaTimes (U.K.)

AstraZeneca's MedImmune unit and NGM Biopharmaceuticals will collaborate in the discovery and development of the latter's enteroendocrine cell program for the treatment of obesity and type 2 diabetes. The firms intend to develop first-in-class peptide and antibody treatments based on the EEC hormones. The deal entitles NGM to upfront payment, research funding, milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX